Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Int J STD AIDS ; 16(12): 807-10, 2005 Dec.
Article in English | MEDLINE | ID: mdl-16336763

ABSTRACT

To analyse if a four-drug combination including two protease inhibitors (PIs) accelerates viral decay and suppression as compared with standard triple therapy in heavily immunosuppressed HIV-1 infected patients, an open label clinical trial was designed. PIs naive patients receiving their first highly active antiretroviral therapy were included if their CD4 cell count was lower than 200/mm3 and their HIV viral load (VL) >100,000 RNA copies/mL. Every patient received two analogues and was randomized in two groups receiving either one PI (saquinavir soft gel capsule) or two PIs (saquinavir + nelfinavir). Viral efficacy (VL <50), time to reach VL <50, viral clearance rate constant and plasmatic elimination half-life were determined. In all, 30 patients were enrolled. No viral variable was significatively improved by the four-drug combination in the short term. No clinical benefit should be expected with a four-drug (two PIs) regimen in patients with low CD4+ cell count and high VL.


Subject(s)
HIV Infections/drug therapy , HIV Protease Inhibitors/therapeutic use , HIV-1/drug effects , Nelfinavir/administration & dosage , Saquinavir/administration & dosage , Adult , Antiretroviral Therapy, Highly Active , Drug Interactions , Drug Therapy, Combination , HIV Protease Inhibitors/adverse effects , HIV Protease Inhibitors/pharmacology , HIV-1/physiology , Humans , Immunosuppression Therapy , Nelfinavir/adverse effects , Saquinavir/adverse effects , Viral Load
SELECTION OF CITATIONS
SEARCH DETAIL
...